🟢 Adaptive Biotechnologies is trading 4.38% up in pre-market while immediate catalyst remains unclear

Adaptive Biotechnologies is trading at $26.01 (+4.38%) in pre-market, while the immediate catalyst remains unclear.

• No new company-specific announcement or overnight catalyst was identified for September 1, 2026.
• The latest major update remains July’s second-quarter 2026 results, which included revenue above estimates and higher MRD guidance.
• The move is occurring despite weaker U.S. futures and broader risk-off sentiment.